Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics

Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics

To date, the most studied drug in anti-aging research is the mTOR inhibitor – rapamycin. Despite its almost perfect anti-aging profile, rapamycin exerts one significant limitation – inappropriate physicochemical properties. Therefore, we have decided to utilize virtual high-throughput screening and...

Full description

Bibliographic Details
Main Authors: Zofia Chrienova, David Rysanek, Patrik Oleksak, Dorota Stary, Marek Bajda, Milan Reinis, Romana Mikyskova, Ondrej Novotny, Rudolf Andrys, Adam Skarka, Pavla Vasicova, Josef Novak, Martin Valis, Kamil Kuca, Zdenek Hodny, Eugenie Nepovimova
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Aging Neuroscience
Subjects:
aging
cancer
mTOR
anti-aging therapy
SASP phenotype
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2022.1048260/full

Internet

https://www.frontiersin.org/articles/10.3389/fnagi.2022.1048260/full

Similar Items